Clinical trials: Scleroderma, Systemic
Scleroderma, Hand Rheumatism
Validity and Reliability of the Turkish Version of HAnDE
The aim of the present study was to translate and cross-culturally adapt The Hand Scleroderma Experienced Experience (HAnDE) Scale into the Turkish language and investigate its reliability and validity in Turkish-speaking…
- Trial name
- NCT06536595
- Testing
- Scales
- Where
- Turkey (Türkiye)
- Volunteers
- 77 people
- Sponsor
- Gazi University
Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis
Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases
This study is a single-arm, intervention, dose-escalation clinical trial to evaluate the safety of allogeneic CD19/BCMA-targeted CAR-γδT cell in the treatment of relapsed/refractory autoimmune diseases
- Conditions
- Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory / Relapsing / Progressive Inflammatory Myopathy, Refractory / Relapsed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
- Trial name
- NCT07490275
- Testing
- Allogeneic CD19/BCMA-targeted CAR-γδT cell injection, Cyclophosphamide, Fludarabine
- Volunteers
- 9 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Scleroderma, Systemic Sclerosis
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
The Scleroderma Patient-centered Intervention Network (SPIN) is an organization established by researchers, health care providers, and people living with scleroderma (systemic sclerosis; SSc) from Canada, the United States…
- Trial name
- SPIN-SELF (NCT04246528)
- Testing
- SPIN-SELF Program
- Where
- Canada
- Volunteers
- 169 people
- Sponsor
- Lady Davis Institute
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Baseline (Day 1) Visit.
- Trial name
- NCT04781543
- Testing
- HZN-825 BID, HZN-825 QD
- Where
- 4 sites in Serbia, Spain
- Volunteers
- 301 people
- Sponsor
- Amgen
Understand Pathogenicity of SSc-specific Antibodies in SSc and the Effect of Antibody Blockade in Vitro
AUTOANTIBODIES AND SYSTEMIC SCLEROSIS
Established in vitro assays, combined with state-of-the-art multi-omics approaches and innovative in vitro experimental models, will gain insights into the mechanistic bases underlying Systemic Sclerosis (SS) pathogenesis and…
- Trial name
- AUTO (NCT06502678)
- Testing
- Fcr blocker of autoantibodies
- Volunteers
- 6 people
- Sponsor
- IRCCS Ospedale San Raffaele
Systemic Sclerosis
Treatment of Systemic Sclerosis With Autologous Regulatory Т-cells
Treatment of patients with systemic sclerosis with autologous regulatory Т-cells
- Trial name
- NCT05214014
- Testing
- Autologous Regulatory Т-cells, Standard treatment according to the clinical protocols
- Where
- Belarus
- Volunteers
- 30 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Systemic Sclerosis Pulmonary, Pulmonary Hypertension
Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement
Progressive SSc is an entity with limited therapeutic alternatives and with asurvival rate of less than 45% in the first 3 to 5 years.
- Conditions
- Systemic Sclerosis Pulmonary, Pulmonary Hypertension, Pulmonary Fibrosis
- Trial name
- NCT04432545
- Testing
- Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly
- Where
- Colombia
- Sponsor
- Universidad de la Sabana
Pulmonary Hypertension
Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) compared to placebo (sugar pill) in the treatment of patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00080457
- Testing
- sitaxsentan sodium
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Encysive Pharmaceuticals
Scleroderma, Scleroderma, Localized
Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma
This study aims to investigate the effectiveness of BETY, an exercise approach based on the biopsychosocial model, in children and adults diagnosed with scleroderma.
- Conditions
- Scleroderma, Scleroderma, Localized, Scleroderma Systemic, Scleroderma (Limited and Diffuse)
- Trial name
- NCT07292961
- Testing
- Cognitive Exercise Therapy Approach, Control group
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- Hacettepe University
Scleroderma
Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
This phase I/II pilot trial seeks to demonstrate that prolonged administration of Campath-1H without prior marrow or stem cell harvesting can result in immunoablation similar to that achieved by hematopoietic stem cell…
- Trial name
- CAMPATH-1H (NCT01639573)
- Testing
- Campath
- Sponsor
- Children's Hospital Los Angeles
Diffuse Cutaneous Systemic Sclerosis
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with diffuse cutaneous systemic sclerosis.
- Trial name
- NCT02465437
- Testing
- JBT-101, Part B Open-Label Extension
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Scleroderma
High Dose Cyclophosphamide for Treatment of Scleroderma
Systemic Sclerosis (Scleroderma) varies greatly in clinical manifestations, mode of presentation, and course. The natural history of this chronic autoimmune disease ranges from benign to fatal.
- Trial name
- NCT00501995
- Testing
- IV Cyclophosphamide
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Systemic Sclerosis, Inflammatory Myopathies
Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory Myopathies
Systemic sclerosis and inflammatory myopathies, which sometimes combine (scleromyositis), have shared pathophysiological elements.
- Trial name
- SCLEROMYOMICS (NCT04917705)
- Testing
- Collection of biological samples
- Where
- France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Strasbourg, France
Systemic Sclerosis, Raynaud Phenomenon
Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot
The goal of this observational pilot data acquisition study is to establish if target users can obtain diagnostic quality images in the clinic, from participants with Systemic Sclerosis (SSc), and SSc spectrum conditions.
- Trial name
- NCT06291142
- Testing
- Observation - Nailfold capillaroscopy
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Systemic Sclerosis, Digital Ulcer
Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers
A randomized controlled trial will be performed to confirm preliminary uncontrolled data indicating that regional adipose tissue grafting is effective in inducing digital ulcer healing in patients with systemic sclerosis.
- Trial name
- ADUL-SSc (NCT03406988)
- Testing
- Autologous fat grafting
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- ASST Gaetano Pini-CTO
Systemic Sclerosis
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
- Trial name
- Breakfree-SSc (NCT07335562)
- Testing
- BMS-986353, Fludarabine, Cyclophosphamide
- Where
- 56 sites in United States, Belgium and 8 more
- Volunteers
- 92 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Systemic Sclerosis, Mesenchymal Stem Cells
Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc)
This study will explore safety and efficacy of allogeneic mesenchymal stem cells transplantation (MSCT) to treat patients with diagnosis of systemic sclerosis(SSc) who have been resistant to multiple standard treatments.
- Trial name
- NCT00962923
- Testing
- Allogeneic Mesenchymal Stem Cells (AlloMSC)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Systemic Sclerosis
Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution® System) in the Hands of Patients Suffering From Systemic Sclerosis
Systemic sclerosis is an autoimmune disease characterized by skin lesions and visceral responsible for significant morbidity. Microcirculatory disorders and tissue fibrosis are excessive severity of the disease.
- Trial name
- NCT01813279
- Testing
- the cell therapy
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Scleroderma
Yoga Adjunct for Scleroderma
This is a pilot research study to determine the feasibility of gentle yoga and breathing exercises for symptom management in patients with scleroderma.
- Trial name
- GYYB (NCT04491396)
- Testing
- Gentle Yoga and Yogic Breathing
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical University of South Carolina